Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The companies press on with vilastobart and IMPT-314... up to a point.
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Could a new ADC project distract attention away from evorpacept?
